Hopae and INCERT Partner to Make Hopae Connect the First EU-Registered Intermediary for a wide adoption and use of EU Digital Identity Wallet
8.9.2025 11:25:00 CEST | Business Wire | Press Release
Hopae Inc., creator of the Hopae Connect – Global eID and Wallet orchestration platform, and INCERT GIE, Luxembourg’s public trust infrastructure agency, today announced a strategic partnership to make Hopae Connect the first officially registered Intermediary Service in the EU under the eIDAS 2.0 regulation.
—
eIDAS 2.0 is the EU regulation that aims to deliver to every European a government-backed Digital Identity Wallet by the end of 2026—and makes it mandatory for banks, airlines, telecoms, and more to accept this new identification means. For citizens, this is a shift as big as the move from cash to contactless payment: proving who you are becomes instant, secure, and borderless. For the industry, this is a challenge given the complexity of integrating the 27 planned wallets released by the Member States. By making Hopae Connect the first EU-registered trusted intermediary, companies subject to the regulation will be able to get access to these eID and Wallet schemes easily and propose them to end user citizens.
With over 450 million Europeans to be equipped with an EUDI Wallet, the scale of change is unprecedented — and the impact will be felt in daily life:
- Opening a bank account abroad → If I’m a French citizen living in Italy, I will be able to open a bank account in minutes online, even at 3 a.m, without the need of taking pictures of my ID document and even if the Bank is a German one.
- At the airport → If I’m traveling abroad, I will be able to board and pass security checks with a single tap instead of juggling passports and documents.
—
The European Digital Identity (EUDI) Wallet, mandated for citizen login and identity verification, must be accepted by regulated digital platforms, such as the banking sector, the telecommunications sector, the gambling sector, or the healthcare one, operating in the EU by 2027. Non-compliance could result in penalties of up to 1% of global annual turnover.
To meet this challenge, Hopae and INCERT are working together to formally register Hopae Connect as the first compliant intermediary platform in Europe. This will give enterprises a ready-made, government-grade service to accept EUDI credentials and aggregate all EU Member States Digital Identity Wallets. Intermediary role has been defined in the eIDAS Architecture Reference Framework as a registered Relying Party providing services to Relying Parties.
Unlike traditional integrations built on generic cloud services, Hopae Connect will be powered by INCERT’s sovereign, eIDAS-compliant infrastructure—a trusted backend already used by some European governments providing Hopae with a Qualified Trusted Service Provider role enabling the evolution of the service to support electronic attestations. This unique design makes Hopae Connect one of the only platforms built from the ground up for regulatory-grade identity orchestration.
“Compliance at this level isn’t just a feature—it’s a foundation,” said Jaehoon Shim, CEO of Hopae. “By running Hopae Connect on INCERT’s trust infrastructure, we help our customers turn regulatory burden into competitive advantage.”
“A fully integrated ecosystem is the key to achieving seamless functionality and wide-scale usage of the EUDI wallet. ” added Benoit Poletti, CEO of INCERT. “Together with Hopae, we are laying it for trusted identity across Europe’s digital economy.”
The partners aim to complete conformity assessment and registration by the end of September 2025, well ahead of the 2027 enforcement deadline.
About Hopae:
Hopae is a digital identity infrastructure platform that helps organizations anticipate and comply with new regulations such as eIDAS 2.0, while staying competitive. Its suite of solutions provides a trusted, sovereign, and scalable foundation for digital identity — enabling higher conversion rates for businesses, reducing fraud, and ensuring more secure and self-sovereign identities for citizens.
About INCERT:
INCERT, established in 2012 by the State of Luxembourg, is a specialist in identity management and cryptographic solutions. The company's original mission was to support Luxembourg's public services, particularly in the issuance of electronic passports and ID cards, e-wallets, the digitalization of health processes, and the traceability of tobacco products. Today, INCERT offers a comprehensive ecosystem of solutions and services to both public and private clients worldwide. Its key missions are to promote digital trust and innovation, to act as a key player in the Luxembourg digital ecosystem, and to help governments and businesses preserve their digital sovereignty.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908848131/en/
Contacts
Media contact INCERT
Karen Bornaghi +33629909493
Media contact — Hopae:
Maïlys Mas
Head of Marketing
mailys@hopae.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom